Viracta Therapeutics, Inc. (VIRX)

NASDAQ: VIRX · Real-Time Price · USD

0.210

-0.004 (-2.05%)

At close: Dec 20, 2024, 4:00 PM

0.228

+0.018 (8.33%)

After-hours: Dec 20, 2024, 7:49 PM EST

Viracta Therapeutics Employees

Viracta Therapeutics had 40 employees as of December 31, 2023. The number of employees increased by 8 or 25.00% compared to the previous year.

Employees

40

Change (1Y)

8

Growth (1Y)

25.00%

Revenue / Employee

n/a

Profits / Employee

-$1,082,225

Market Cap

8.35M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	40	8	25.00%
Dec 31, 2022	32	8	33.33%
Dec 31, 2021	24	-	-

Related Stocks

Company Name	Employees
Meihua International Medical Technologies	617
XWELL	337
Evogene	142
Mustang Bio	80
RedHill Biopharma	53
Aethlon Medical	14
COSCIENS Biopharma	12
CERo Therapeutics Holdings	9

Employee Rankings

VIRX News

5 weeks ago - Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
4 months ago - Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
4 months ago - Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - GlobeNewsWire
7 months ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
7 months ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
8 months ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
8 months ago - Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
8 months ago - Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma - GlobeNewsWire